Linder C., Heusch G.: ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther1990;4:1375-84.
2.
Lindpaintner K., Wilhelm MJ, Jin M. et al. Tissue renin-angiotensin systems: Focus on the heart. J Hypertens1987 ;5 (suppl 2):S33-S38.
3.
HirschAT,Talsness CE, Schunkert H., Paul M., Dzau VJTissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res1991;69:475-82.
4.
Danser,AHJSaris JJ, Schuijt MP, van Kats JP: Is there a local renin-angiotensin system in the heart? Cardiovasc Res1999;44:252-65.
5.
Ertl G., Kloner RA,Alexander RW, Braunwald E.Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation1982;65:40-8.
6.
McAlpine HM, Cobbe SMNeuroendocrine changes in acute myocardial infarction. Am J Med1988;84 (suppl 3A):61-6
7.
Noda K., Sasaguri M., Ideishi M., Ikeda M.,Arakawa K.Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res1993;27: 334-40.
8.
Balcells E., Meng QC, Johnson J.r. WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol1997;42:H1769-H1774.
9.
Hollenberg NKImplications of species difference for clinical investigation. Studies on the renin-angiotensin system. Hypertension2000;35 [part 2]:150-4.
10.
Baumgarten CR, Linz WL, Kunkel G., Schölkens BA, Wiemer G.Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol1993 ;108:293-5.
11.
Timmermans Pbmwm, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev1993 ;45:205-51.
12.
Paradis P., Dali-Youcef N., Paradis FW,Thibault G., Nemer M.Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA2000;97:931-6.
13.
Mukoyama M. , Nakajima M., Horiuchi M., Sasamura H., Pratt RE, Dzau VJExpression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem1993;268:24539-42.
14.
Scheuer DA, Perrone MHAngiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol1993 ;33:R917-R923.
15.
Akishita M. ,Yamada H., Dzau VJ, Horiuchi M.Increased vasoconstrictor response of the mouse lacking angiotensin II Type 2 receptor. Biochem Biophys Res Commun1999;261:345-9. 16. HunleyTE, Tamura M., Stoneking BJ et al.The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice. Kidney Int2000;57:570-7.
16.
Stoll M., Steckelings UM, Bottari SP, Metzger R., UngerT.The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest1995;95:651-7.
17.
Hübner R., Högemann AM, Sunzel M., Riddell JGPharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens1997; 11(Suppl 2):S19-S25.
18.
Liu Y.-H, Yang X.-P, Sharov VG, Nass O., Sabbah HH, Peterson E., Carretero OAEffects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest1997;99:1926-35.
19.
Wiemer G., Schölkens BA, Busse R., Wagner A., Heitsch H., Linz W.The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett1993;3:24-7.
20.
Seyedi N., Xu XB, Nasjletti A., Hintze THCoronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension1995; 26:164-70.
21.
Carey RM, Jin X.-H, Wang Z.-Q, Siragy HMNitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor . Acta Physiol Scand2000;168:65-71.
22.
Kuga T., Mohri M., Egashira K. et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol1997;30:108-12.
23.
Martorana PA , Kettenbach B., Breipohl G., Linz W., Schölkens BAReduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol1990;182:395-6.
24.
Werrmann JG , Cohen SMComparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol1994;24:573-86.
25.
Werrmann JG , Cohen SMUse of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol1996 ;27:177-82.
26.
Paz Y., Gurevitch J., Frolkis I. et al. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts. Ann Thorac Surg1998;65:474-9.
27.
Ford WR, Clanachan AS, Jugdutt BIOpposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation1996;94:3087-9.
28.
Massoudy P. , Becker BF, Gerlach E.Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat . J Cardiovasc Pharmacol1994;23:632-9.
29.
Dörge H., Behrends M., Schulz R., Jalowy A., Heusch G.Attenuation of myocardial stunning by AT1receptor antagonist candesartan . Basic Res Cardiol1999;94:208-14.
30.
van Gilst WH , de Graeff PA, Wesseling H., de Langen CDJ.Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors:A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol1986;8:722-8.
31.
Ehring T.,Baumgart D., Krajcar M., Hümmelgen M., Kompa S., Heusch G.Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation1994;90:1368-85.
32.
Hohlfeld T. , Strobach H., Schrör K.Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial `stunning` . J Cardiovasc Pharmacol1991;17:108-15.
33.
Shimizu M., Wang Q.-D, Sjöquist P-O., Rydén L.The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts . J Cardiovasc Pharmacol1999;34:78-81.
34.
Yoshiyama M. , Kim S., Yamagishi H. et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J1994;128:1-6.
35.
Wang Q.-D. Sjöqist P-O. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol1999 ;380:13-21.
36.
Hoshida S., Yamashita N., Kuzuya T., Hori M.Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis2000;149:287-94.
37.
Preckel B., Schlack W., González M., Obal D., Bathel H., Thämer V.Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol2000;95:404-12.
38.
Hartman JC, Hullinger TG, Wall TM, Shebuski RJReduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol1993 ;234:229-36.
39.
Liu Y., Tsuchida A., Cohen MV, Downey JMPretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol1995;27:883-92.
40.
Diaz RJ, Wilson GJSelective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol1997;29:129-39.
41.
Shimizu M.,Wang Q.-D, Sjöquist P-O., Ryden L.Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol1998;32:231-8.
42.
Shimizu M., Wang Q.-D, Sjöquist P-O., Rydén L.The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther1999;13:347-53.
43.
Shimizu M.,Wang Q.-D, Sjöquist P-O., Ryden L.Combination of a calcium antagonist, a lipid peroxidation inhibitor , and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. J Cardiovasc Pharmacol1999;34:512-7.
44.
JalowyA,Schulz R., Dörge H., Behrends M., Heusch G.Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol1998;32:1787-96.
45.
Weidenbach R., Schulz R., Gres P., Behrends M., Post H., Heusch G.Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism . BrJPharmacol2000; 131:138-44.
46.
Liu Y.-H, Yang X.-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OAParacrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension1996;27:7-13.
47.
Sladek T., Sladkova J., Kolar F. et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res1996;31:568-76.
48.
Richard V., Ghaleh B., Berdeaux A., Giudicelli J-F.Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs . Br J Pharmacol1993;110:969-74.
49.
Zhu B.-Q, Sun Y.-P, Sievers RE et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol2000;35:787-95.
50.
Xu Y., Menon V., Jugdutt BICardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-e in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKCe proteins. JRAAS2000;1:184-95.
51.
Schwarz ER, Montino H., Fleischhauer J., Klues HG, vom Dahl J., Hanrath P.Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther1997;11:687-95.
52.
Hartman JC, Wall TM, Hullinger TG, Shebuski RJReduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol1993;21:996-1003.
Liang C-S., Gavras H., Black J., Sherman LG, Hood Jr. WBRenin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation1982 ;66:1249-55.
55.
Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJEffects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol1984;6:1043-7.
56.
Jalowy A., Schulz R., Heusch G.AT1 receptor blockade in experimental myocardial ischemia/reperfusion . Basic Res Cardiol1998;93 (Suppl 2):85-91.
57.
Seyedi N., Xu XB, Nasjletti A., Hintze THCoronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension1995;26:164-70.
58.
de Carvalho Frimm C., Sun Y., Weber KTAngiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med1997;129:439-46.
59.
Gaussin V., Schneider MDSurviving infarction one gene at a time. Decreased remodeling and mortality in engineered mice lacking the angiotensin II type 1A receptor. Circulation1999;100:2043-4.
60.
Harada K., Sugaya T., Murakami K., Yazaki Y., Komuro I.Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation1999;100:2093-9.
61.
Yamagishi H. , Kim S., Nishikimi T., Takeuchi K., Takeda T.Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol1993;25:1369-80.
62.
Nishikimi T. , Yamagishi H., Takeuchi K., Takeda T.An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats . Cardiovasc Res1995;29:856-61.
63.
Schieffer B. , Wirger A., Meybrunn M. et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation1994;89:2273-82.
64.
KohyaT.,Yokoshiki H.,Tohse N. et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res1995;76:892-9.
65.
Gervais M., Richer C., Fornes P., de Gasparo M., Giudicelli J-F.Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol1999;13:635-45.
66.
van Kats JP , Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction. Role of tissue angiotensin II. Circulation2000;102:1556-63.
67.
DuncanA-M ,James GM,Anastasopoulos F., KladisA ,Briscoe TA, Campbell DJInteraction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels . J Pharmacol and Exper Ther1999;289:295-303.
68.
Lefkowitz RJ , Rockman HA, Koch WJCatecholamines, cardiac b-adrenergic receptors, and heart failure. Circulation2000;101:1634-7.
69.
Spinale FG, Iannini JP, Mukherjee R., Malton DM, de Gasparo M.Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: Cellular mechanisms of action. J Card Fail1998;4:325-32.
70.
Spinale FG, de Gasparo M., Whitebread S. et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems. Circulation1997;96:2385-96.
71.
Krombach RS , Clair MJ, Hendrick JW et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns . Cardiovasc Res1998;38:631-45.
72.
The Acute Infarction Ramipril Efficacy (AIRE) Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet1993;342:821-8.
73.
Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med1992;327:669-77.
74.
Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE) . Lancet1997;349:747-52.
75.
Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet2000;355:1582-7.
76.
McKelvie RS ,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation1999;100:1056-64.
